NASDAQ:CTOR Citius Oncology Q2 2025 Earnings Report $0.70 +0.02 (+2.44%) As of 11:53 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Citius Oncology EPS ResultsActual EPS-$0.11Consensus EPS -$0.09Beat/MissMissed by -$0.02One Year Ago EPSN/ACitius Oncology Revenue ResultsActual RevenueN/AExpected Revenue$5.74 millionBeat/MissN/AYoY Revenue GrowthN/ACitius Oncology Announcement DetailsQuarterQ2 2025Date5/14/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time7:00AM ETUpcoming EarningsCitius Oncology's Q3 2026 earnings is estimated for Tuesday, August 18, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Citius Oncology Earnings HeadlinesCitius Oncology Inc CTORJuly 1, 2026 | morningstar.comMCitius Oncology (NASDAQ:CTOR) Shares Up 11.5% - Time to Buy?June 30, 2026 | americanbankingnews.comThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big Tech and Washington policymakers. It can be trucked to a data center, military base, or industrial site and deliver reliable power for years without grid access. A key government milestone expected this August could bring significant visibility to this space. One small stock sits at the center of it.July 6 at 1:00 AM | Monument Traders Alliance (Ad)Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory ...June 1, 2026 | finance.yahoo.comCitius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic MalignanciesJune 1, 2026 | prnewswire.comCitius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual MeetingMay 26, 2026 | prnewswire.comSee More Citius Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Citius Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Citius Oncology and other key companies, straight to your email. Email Address About Citius OncologyCitius Oncology (NASDAQ:CTOR) is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.View Citius Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponVisa’s Open USD Push Puts Circle’s Stablecoin Moat Under PressureGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price TargetsIs the Memory Rally Still Alive After the Semiconductor Sell-Off? Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
